MoonLake Immunotherapeutics (MLTX) Misses Q1 EPS by 9c

MoonLake Immunotherapeutics (NASDAQ: MLTX) reported Q1 EPS of ($0.98), $0.09 worse than the analyst estimate of ($0.89).

For earnings history and earnings-related data on MoonLake Immunotherapeutics (MLTX) click here.

You May Also Be Interested In

• Warsh: Inflation Data Don’t Suggest Trend Meaningfully Improved
• Benchmark Reiterates Buy Rating on Malibu Boats (MBUU) on Significant Earnings Upside
• Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak